Keratinocyte Carcinoma Clinical Trial
Official title:
The Effectiveness of the Teach-back Method on Patient Satisfaction and Adherence to Wound Care Regimen After Mohs Micrographic Surgery: A Pilot Study
The purpose of this study is to examine a different way to educate patients about taking care of their wound and see how this method affects patient satisfaction, compliance to the wound care regimen, and patient experience. The teach-back method is delivered using the ask-tell-ask method. Investigators will ask the patient about their knowledge of wound care healing, provide the patient educational component, then ask the patient to repeat what was said. If the answer is wrong or incomplete, the researcher will go over the information again with the patient to clear up any misunderstandings.
Patients undergoing Mohs Micrographic surgery for skin cancers on the lower extremities for the first time that are left to heal by secondary intention are randomized either to receive a scripted teach-back session or a standard of care wound care education. This study wishes to compare wound care adherence, patient experience, wound complications, and the number of phone calls made by patients to the office between the two cohorts primary objective is to determine whether study participants who have received the teach-back method have an increase wound care adherence at one week post-operatively, compared to those who received the standard of care. To characterize differences in the patient experience between the two interventional groups 2 weeks after surgery. To determine whether the number of phone calls made post-operatively by patients will decrease in a 2 week follow-up time period. To characterize the differences in patient wound care adherence at 2 weeks after surgery. To determine whether there is a difference in complication incidence post-operatively ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05955924 -
Nicotinamide Chemoprevention for Keratinocyte Carcinoma in Solid Organ Transplant Recipients - Pivotal Trial
|
Phase 3 |